Wellgistics Health Launches XRP Payments, Seeks Capital via S-1/A

TL;DR

**WGRX's S-1/A is a high-risk play, as the company is raising capital with no minimum, potentially leaving investors exposed to an underfunded blockchain-enabled healthcare vision.**

AI Summary

Wellgistics Health, Inc. (WGRX) filed an S-1/A on September 12, 2025, outlining a public offering of common stock, warrants, and pre-funded warrants. The company, founded in 2022, operates as a holding company for pharmaceutical and healthcare services, with key subsidiaries including Wood Sage LLC, Wellgistics, LLC, Wellgistics Tech & Hub, LLC, and Wellgistics Pharmacy, LLC. WGRX completed the acquisition of Wood Sage on June 16, 2024, and Wellgistics, LLC on August 30, 2024. In April 2025, WGRX entered into an agreement to acquire Peek Healthcare Technologies, Inc., a digital prescription platform. A significant recent development is the August 2025 launch of a blockchain-based payment integration leveraging the XRP Ledger (XRPL) to facilitate secure, low-cost, real-time payments with pharmacy customers, offering XRP as an alternative payment method. The company intends to immediately convert received XRP into U.S. dollars. The offering has no minimum proceeds, meaning WGRX may sell fewer than all securities, potentially impacting its ability to achieve business goals.

Why It Matters

This S-1/A filing is crucial for investors as Wellgistics Health (WGRX) is seeking capital without a minimum offering amount, which could lead to significant dilution and uncertainty regarding its ability to fund its ambitious 'micro health ecosystem' strategy. The integration of XRP Ledger for payments could be a differentiator in the competitive healthcare and pharmaceutical distribution market, potentially attracting tech-savvy investors and improving operational efficiency. However, the lack of an established public trading market for the warrants and pre-funded warrants limits liquidity for those securities. For employees and customers, the expansion through acquisitions like Peek Healthcare Technologies suggests growth and broader service offerings, but the financial risks associated with the offering structure could impact long-term stability.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit statement that "there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering." This means WGRX may sell fewer than all securities, which "may significantly reduce the amount of proceeds received by us," and investors "will not receive a refund." Furthermore, investors "could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering."

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate WGRX's financial health and business plan given the 'no minimum' offering structure. Consider the potential for significant dilution and the company's ability to execute its strategy, especially the novel XRP payment integration, without guaranteed funding. This offering is speculative and best suited for investors with a high-risk tolerance.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $0.0001 — Par value per share (Par value of Common Stock and exercise price for Pre-Funded Warrants)
• 7.0% — Placement Agent cash fee (Percentage of gross proceeds paid to the Placement Agent)
• $100,000 — Placement Agent legal and out-of-pocket expense reimbursement cap (Maximum amount WGRX will reimburse the Placement Agent for expenses)
• $15,950 — Placement Agent clearing expenses (Amount WGRX will reimburse the Placement Agent for clearing expenses)
• 125% — Placement Agent Warrants exercise price (Exercise price for Placement Agent Warrants relative to the public offering price)
• 2022 — Company founding year (Year Wellgistics Health, Inc. was founded)
• 2025-09-12 — S-1/A filing date (Date the Amendment No. 2 to Form S-1 was filed with the SEC)
• 2025-08 — XRP Ledger launch month (Month Wellgistics launched its blockchain-based payment integration leveraging the XRP Ledger)

Key Players & Entities

• Wellgistics Health, Inc. (company) — Registrant and holding company for healthcare services
• WGRX (company) — Ticker symbol on Nasdaq Capital Market
• Wood Sage LLC (company) — Wholly owned subsidiary acquired on June 16, 2024
• Wellgistics, LLC (company) — Wholly owned subsidiary acquired on August 30, 2024, a pharmaceutical distributor
• Wellgistics Tech & Hub, LLC (company) — Indirect subsidiary focusing on back-end healthcare technology
• Wellgistics Pharmacy, LLC (company) — Indirect subsidiary operating as a community pharmacy
• Peek Healthcare Technologies, Inc. (company) — Pioneering digital prescription platform to be acquired in April 2025
• Brian Norton (person) — Agent for service and owner of Wellgistics, LLC
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• $1.53 (dollar_amount) — Last reported sale price of WGRX Common Stock on Nasdaq on September 11, 2025

FAQ

Risk Factors

• Dependence on Key Acquisitions [high — operational]: The company's business model relies heavily on the successful integration and performance of recently acquired entities, including Wood Sage LLC (acquired June 16, 2024) and Wellgistics, LLC (acquired August 30, 2024). Failure to effectively integrate these businesses or achieve their projected operational and financial contributions could materially and adversely affect the company's business, financial condition, and results of operations.
• Competition in Pharmaceutical and Healthcare Services [medium — market]: Wellgistics Health operates in a highly competitive landscape within the pharmaceutical and healthcare services sectors. The company faces competition from established players and emerging companies, which could impact market share, pricing power, and profitability. The success of its digital prescription platform acquisition (Peek Healthcare Technologies, Inc.) is also subject to competitive pressures in the digital health space.
• Regulatory Compliance in Healthcare and Pharma [high — regulatory]: As a holding company for pharmaceutical and healthcare services, Wellgistics Health is subject to extensive and evolving federal, state, and local regulations. Non-compliance with regulations related to drug distribution, patient privacy (HIPAA), and healthcare services could result in significant penalties, reputational damage, and operational disruptions.
• No Minimum Offering Proceeds [high — financial]: The S-1/A filing indicates no minimum proceeds for the public offering. This means the company may sell fewer securities than planned, potentially resulting in insufficient capital to fund its business objectives, including the integration of acquisitions and expansion of services. This lack of a funding floor introduces uncertainty regarding the company's ability to execute its growth strategy.
• Reliance on Blockchain Technology and XRP [medium — operational]: The company's recent launch of a blockchain-based payment integration using the XRP Ledger (XRPL) introduces new operational and technological risks. Dependence on this novel technology, including its security, scalability, and regulatory acceptance, is critical. Any disruptions or issues with the XRPL or the company's integration could impact payment processing and customer transactions.
• Volatility of Cryptocurrency Payments [low — market]: While the company intends to immediately convert XRP to USD, the use of XRP as an alternative payment method exposes it to the inherent volatility of cryptocurrency markets. Fluctuations in XRP's value could impact the effective cost of transactions or create accounting complexities, even with immediate conversion.

Industry Context

Wellgistics Health operates within the dynamic pharmaceutical and healthcare services sectors, which are characterized by increasing consolidation, technological innovation, and stringent regulatory oversight. The company's strategy involves acquiring and integrating various healthcare entities, including pharmacies and technology platforms, to create a diversified business. Key trends include the growing demand for efficient prescription fulfillment, the adoption of digital health solutions, and the exploration of alternative payment methods, such as blockchain technology.

Regulatory Implications

The company's operations in the pharmaceutical and healthcare sectors expose it to significant regulatory scrutiny. Compliance with federal and state laws governing drug distribution, patient data privacy (e.g., HIPAA), and healthcare provider licensing is paramount. The use of blockchain technology for payments, while innovative, may also attract future regulatory attention regarding financial transactions and digital assets.

What Investors Should Do

1. Evaluate the integration success of recent acquisitions (Wood Sage LLC, Wellgistics, LLC).
2. Assess the competitive landscape for digital prescription platforms.
3. Monitor the operational and regulatory risks associated with the XRP Ledger payment integration.
4. Consider the implications of the 'no minimum proceeds' clause in the offering.

Key Dates

• 2022-01-01: Company Founding — Marks the inception of Wellgistics Health, Inc. as a holding company.
• 2024-06-16: Acquisition of Wood Sage LLC — Significant step in building the company's pharmaceutical and healthcare services portfolio.
• 2024-08-30: Acquisition of Wellgistics, LLC — Further expansion of the company's operational footprint and service offerings.
• 2025-04-01: Agreement to Acquire Peek Healthcare Technologies, Inc. — Indicates a strategic move into digital health and prescription platforms.
• 2025-08-01: Launch of XRP Ledger Payment Integration — Introduction of innovative blockchain-based payment solutions, signaling a forward-looking approach to financial transactions.
• 2025-09-12: S-1/A Filing Date — Public disclosure of the company's offering details, financial information, and business strategy to potential investors.

Glossary

S-1/A

An amended registration statement filed with the U.S. Securities and Exchange Commission (SEC) to provide updated or corrected information before an initial public offering (IPO) or other securities offering. (This is the document detailing Wellgistics Health's public offering, including its business, financials, and risks.)

Common Stock

A class of stock that represents ownership in a corporation and typically carries voting rights, but has a lower claim on assets and earnings than preferred stock. (The primary security being offered to the public by Wellgistics Health.)

Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price within a specified timeframe. (Offered alongside common stock and pre-funded warrants, these provide additional potential upside for investors and incentives for placement agents.)

Pre-funded Warrants

A type of warrant that allows an investor to purchase stock at a nominal exercise price (e.g., $0.0001), effectively allowing them to acquire shares immediately at a lower upfront cost than buying common stock directly, while deferring a small portion of the purchase price. (These are offered to allow investors to acquire shares at a lower initial cost, potentially avoiding certain ownership thresholds or tax implications.)

XRP Ledger (XRPL)

A decentralized, public blockchain technology designed for fast, low-cost, and secure digital asset transactions, often associated with the cryptocurrency XRP. (Wellgistics Health is leveraging this technology for its payment integration, aiming for efficient transactions with pharmacy customers.)

Placement Agent

A financial institution that assists a company in selling its securities to investors during a public offering. (The Placement Agent is involved in the distribution of Wellgistics Health's securities and receives fees and warrants for its services.)

Year-Over-Year Comparison

As this is an S-1/A filing, it represents an amendment to an initial registration statement. Therefore, a direct comparison of key metrics like revenue growth or margin changes to a prior year's filing is not applicable in the traditional sense. However, the S-1/A provides updated information on the company's recent acquisitions (Wood Sage LLC and Wellgistics, LLC completed in 2024) and strategic initiatives, such as the planned acquisition of Peek Healthcare Technologies, Inc. and the launch of its XRP Ledger payment integration in August 2025, indicating significant recent business development and strategic shifts.

Key Financial Figures

• $0.0001 — o shares of our Common Stock, par value $0.0001 per share (the “ Common Stock &rd
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $1.53 — ck on Nasdaq on September 11, 2025, was $1.53 per share. There is no established publ
• $100,000 — t-of-pocket expenses in an amount up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $0.55 — XRP traded within a range of less than $0.55 to above $3.60 per token, of which pric
• $3.60 — hin a range of less than $0.55 to above $3.60 per token, of which price volatility is
• $50 million — the escrow account to be released, with $50 million ultimately being paid by the promoters

Filing Documents

• forms-1a.htm (S-1/A) — 2053KB
• ex10-20.htm (EX-10.20) — 8KB
• ex23-1.htm (EX-23.1) — 5KB
• formdrs_001.jpg (GRAPHIC) — 16KB
• forms-1_002.jpg (GRAPHIC) — 152KB
• forms-1a_003.jpg (GRAPHIC) — 407KB
• ex10-20_001.jpg (GRAPHIC) — 1507KB
• ex10-20_002.jpg (GRAPHIC) — 1457KB
• ex10-20_003.jpg (GRAPHIC) — 1577KB
• ex10-20_004.jpg (GRAPHIC) — 1671KB
• ex10-20_005.jpg (GRAPHIC) — 1622KB
• ex10-20_006.jpg (GRAPHIC) — 1185KB
• ex10-20_007.jpg (GRAPHIC) — 1409KB
• ex10-20_008.jpg (GRAPHIC) — 1619KB
• ex10-20_009.jpg (GRAPHIC) — 460KB
• ex10-20_010.jpg (GRAPHIC) — 456KB
• 0001493152-25-013281.txt ( ) — 20713KB

USE OF PROCEEDS

USE OF PROCEEDS 11 CAPITALIZATION 12

DILUTION

DILUTION 13 INDUSTRY AND MARKET DATA 14

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 35 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 41 MANAGEMENT 47 Director Compensation 51

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 51 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 52 PLAN OF DISTRIBUTION 55 LEGAL MATTERS 58 EXPERTS 58 INFORMATION INCORPORATED BY REFERENCE 59 WHERE YOU CAN FIND MORE INFORMATION 59 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS As used in this prospectus, unless the context otherwise requires, references to “ Wellgistics Health ,” the “ Company ,” “ we ,” “ us ,” “ our ” and similar terms refer to Wellgistics Health, Inc., a Delaware corporation, and our consolidated subsidiaries. References to shares of “ Common Stock ” refer to shares of our common stock, par value $0.0001 per share. We are offering to sell, and seeking offers to buy, shares of our Common Stock only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus and the offering of our Common Stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our Common Stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. You should rely only on the information contained in this prospectus, any related free-writing prospectus, and any prospectus to which we have referred you. Neither we nor the Placement Agent has authorized any other person to provide you with information different from that contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or

View Full Filing

View this S-1/A filing on SEC EDGAR